Fecal Microbiota Safe, Effective In Preventing Recurrent CDI In Patients With Immunocompromising Conditions, Study Finds

Infectious Disease Advisor (5/7, Basilio) reports a study found that Rebyota (fecal microbiota, live-jslm) “is safe and efficacious against recurrent Clostridioides difficile infection (CDI) in patients with immunocompromising conditions.” Researchers observed that “in the 8 weeks following RBL administration, 44.7% of immunocompromised patients and 48.0% of immunocompetent patients experienced” treatment-emergent adverse effects (TEAEs). Patients with immunocompromising conditions “exhibited lower rates of infection but higher rates of severe TEAEs during this period when compared with those who were immunocompetent.” Overall, immunocompromised and immunocompetent patients “achieved similar rates of treatment success (75.7% and 73.3%, respectively) and sustained clinical response through 6 months (88.7% and 91.6%, respectively). Moreover, the researchers noted comparable efficacy outcomes across the subgroups.” The study was published in Open Forum Infectious Diseases.